Deals, Development and Manufacturing

Nona Biosciences Partners with Boostimmune on ADC Development

February 28, 2024

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen

February 27, 2024

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.

GSK Seeks to Expand its Respiratory Biologics Portfolio with Aiolos Acquisition

February 21, 2024

GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.

BioVaxys Acquires Full Portfolio of Former IMV

February 15, 2024

BioVaxys has acquired the full portfolio of discovery, preclinical, and clinical development-stage assets of the former IMV.

Samsung Biologics Partners with LegoChem Biosciences on ADCs

February 12, 2024

Under the new partnership, Samsung Biologics will develop and manufacture an antibody for a LegoChem Biosciences ADC candidate.

Novartis to Acquire MorphoSys for Roughly $2.9 Billion

February 08, 2024

Through a €2.7 billion (US$2.9 billion) acquisition of MorphoSys, Novartis will get pelabresib, a late-stage drug candidate in development for cancer treatment.

Novo Holdings to Acquire Catalent in Deal Valued at $16.5 billion

February 05, 2024

Novo Holdings has entered into a merger agreement with Catalent and will acquire Catalent in a deal valued at $16.5 billion.

Latest Acquisition Sees ProductLife Group Expand its Asia-Pacific Footprint

February 03, 2024

ProductLife Group has announced its acquisition of Australian company Commercial Eyes.

Agilent and Incyte Collaborate on Development of CDx in Hematology and Oncology

February 02, 2024

Agilent Technologies and Incyte have signed an agreement to collaborate on the development of companion diagnostics programs.

Regeneron Forms R&D Cell Therapy Unit from 2seventy bio Platform Acquisition

February 01, 2024

With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.